Who Brands - Brand Ownership DirectoryWho Brands
HomeBrowse BrandsCategoriesCompaniesCompareBlogQuizAbout
HomeBrowse BrandsCategoriesCompaniesCompareBlogQuizAbout
Who Brands

Your trusted reference for brand ownership information. We provide factual, comprehensive data about who owns the brands you know.

Stay in the know

Get the latest ownership updates delivered to your inbox.

Browse

  • All Brands
  • Categories
  • Companies
  • Countries
  • Compare Brands
  • Blog
  • Brand Quiz
  • RSS Feed

Company

  • About Us
  • Methodology
  • Contact
  • FAQ
  • Submit a Brand
  • List Your Brand
  • Write for Us

Legal

  • Terms of Service
  • Privacy Policy
  • Cookie Policy
  • Affiliate Disclosure
  • Disclaimer

Support Us

☕Buy me a coffee

2026 Who Brands. All information is provided for educational purposes. Brand names and logos are trademarks of their respective owners.

  1. Home
  2. Brands
  3. Healthcare & Pharmaceuticals
  4. Metamucil
Metamucil logo
Healthcare & Pharmaceuticals

Who Owns Metamucil?

Metamucil is owned by Procter & Gamble (NYSE: PG), a publicly traded consumer goods corporation headquartered in Cincinnati, Ohio. P&G acquired Metamucil in 1985 through its purchase of Richardson-Vicks. Metamucil is the leading fiber supplement brand in the United States with approximately 30% market share.

Parent Company

Procter & Gamble Company

Acquired

1985

Status

Publicly Traded

Headquarters

Cincinnati, Ohio, United States

Metamucil Timeline

1837
Procter & Gamble Company

Parent company established in Cincinnati, Ohio, USA

Company Founded
1934

Metamucil

Founded by G. D. Searle & Company

Founded
1985
Acquired by Procter & Gamble Company

Procter & Gamble Company acquired Metamucil

Acquired
mid rangemass marketUnited StatesOfficial Website

Who Owns Metamucil?

  • Parent Company: Procter & Gamble Company
  • Ownership Type: Wholly owned
  • Acquisition Year: 1985
  • Company Type: Publicly Traded
  • Stock Ticker: NYSE: PG
BrandParent CompanyOwnership Type
MetamucilProcter & Gamble CompanyWholly owned

Where to Buy

Disclosure: We may earn commission from purchases
AmazonMetamucil on Amazon

History of Metamucil

  • Founded: 1934
  • Founders: G. D. Searle & Company
  • Acquired by Procter & Gamble Company: 1985

Metamucil was introduced in 1934 by G. D. Searle & Company as a bulk-forming fiber laxative made from psyllium husk. The product was developed to provide a natural approach to promoting digestive regularity through dietary fiber supplementation. Psyllium husk, derived from the Plantago ovata plant, has been used in traditional medicine for centuries as a natural laxative.

The brand name combines "meta" (meaning change or beyond) with "mucil" (referring to the mucilage properties of psyllium). In the 1930s and 1940s, the product gained recognition among physicians and pharmacists as an effective treatment for constipation. Distribution was initially limited to pharmacies and medical channels.

In the 1960s and 1970s, Metamucil expanded its product line with flavored powder formulations to improve taste and patient compliance. The brand also began investing in clinical research to demonstrate health benefits of psyllium fiber beyond laxative effects. Studies published in peer-reviewed journals showed that psyllium fiber could help lower cholesterol levels and improve blood sugar management. These findings allowed the brand to expand its health claims over time.

Richardson-Vicks acquired Metamucil from Searle as part of its expansion into health care products. Under Richardson-Vicks, the brand introduced new delivery formats including capsules and wafers, making the product more convenient for consumers who did not want to mix powder into water.

In 1985, Procter & Gamble acquired Richardson-Vicks for approximately $1.2 billion. The deal brought Metamucil, Vicks, and other brands into P&G's portfolio. Under P&G's ownership, Metamucil continued to expand its product range. The brand added sugar-free formulations, gummies, and additional flavors. P&G also leveraged its marketing and distribution infrastructure to expand Metamucil's availability from pharmacies to mass retail channels including grocery stores, big-box retailers, and online marketplaces.

In September 2024, P&G launched Metamucil Fiber Gummies in major retail chains across North America. The gummy format targets consumers who find powder and capsule formats inconvenient or unpalatable. This launch reflected a broader trend in the supplement industry toward gummy delivery formats.

As of 2026, Metamucil remains the number one doctor-recommended fiber brand, based on ProVoice survey data from 2023. The brand's psyllium-based products are the only leading fiber supplement powered by psyllium husk, according to P&G's marketing materials, which differentiate the brand from competitors like Benefiber (wheat dextrin) and Citrucel (methylcellulose).

About Procter & Gamble Company

Procter & Gamble delivered mixed financial results in fiscal 2026, reflecting both the strength of its business model and challenges in the current consumer environment. In Q2 2026, P&G reported adjusted earnings per share of $1.88, exceeding Wall Street expectations of $1.86, while revenue of $22.21 billion fell slightly short of analyst expectations of $22.28 billion. The company's ability to beat earnings estimates despite revenue challenges demonstrates the effectiveness of its productivity initiatives and cost management strategies.

Financial Performance Overview shows P&G's resilience in a challenging market. The company revised its fiscal 2026 earnings outlook to 1% to 6% net earnings per share growth, down from the previous forecast of 3% to 9%, citing higher restructuring charges. Despite this adjustment, P&G maintained its sales growth guidance, reflecting confidence in its business fundamentals and strategic positioning. CFO Andre Schulten noted that "We've now completed what we fully expect will be the softest quarter of the fiscal year," indicating anticipation of improved performance in the second half.

Volume Performance revealed significant challenges across key categories, with overall volume falling 1% as three out of five product categories reported shrinking volume. This decline reflects broader consumer behavior patterns as inflation-weary consumers hunt for deals and reduce discretionary spending, particularly in P&G's largest market, the United States. Despite these challenges, Schulten emphasized that "People have not stopped washing their hair, they still buy diapers, they do their laundry — albeit at a little bit slower pace, so the market growth has certainly slowed over the last 18 to 24 months."

Segment Performance showed divergent trends across P&G's business portfolio. The baby, feminine and family care segment experienced the steepest decline with volume falling 5% in Q2 2026, facing tough comparisons with the year-ago period when retailers and consumers stocked up ahead of expected port strikes. The grooming business, which includes Gillette and Venus razors, reported a 2% volume drop, reflecting ongoing competitive pressures in the men's grooming market. The health-care segment saw volume fall 1%, including brands like Oral-B, Vicks, and Pepto-Bismol.

Bright Spots in Performance were primarily in the beauty segment, which was the only division to report volume growth, rising 3% fueled by stronger demand for hair-care products. The fabric and home-care business, which includes brands like Febreze and Tide, reported unchanged volume, demonstrating stability in P&G's largest business segment by revenue. These performance variations highlight the importance of P&G's diversified portfolio strategy in navigating market challenges.

Q1 2026 Results demonstrated stronger performance compared to Q2, with net sales of $22.4 billion, up 3% versus the prior year, and organic sales increasing 2%. The company achieved diluted EPS of $1.95 (up 21% YoY) and core EPS of $1.99 (up 3% YoY), reflecting strong operational execution. Operating cash flow was $5.4 billion, and the company returned $3.8 billion to shareholders through dividend payments and share repurchases, demonstrating P&G's commitment to shareholder returns.

Consumer Market Dynamics continue to shape P&G's performance, with the company facing "softer consumer markets, aggressive competition, and a dynamic geopolitical landscape" according to CFO Schulten. These challenges reflect broader economic pressures affecting consumer spending patterns and competitive intensity in key categories. However, P&G expects stronger results in the second half of the fiscal year, fueled by upcoming innovation and improved market conditions.

Innovation and Demand Creation remain central to P&G's strategy for driving growth. The company is increasing investment in innovation and demand creation to improve value for consumers and drive category growth. This focus on innovation is particularly important in the beauty segment, where new product development and marketing initiatives have helped drive volume growth despite overall market challenges.

Q3 2026 Results showed a significant acceleration in performance. P&G reported net sales of $21.24 billion, up 7% versus the prior year, beating Wall Street expectations of $20.5 billion. Organic sales increased 3%, driven by a 2% increase in volume — the first time in a year that P&G reported growing volume across the company. Core EPS of $1.59 beat estimates of $1.56, up 3% YoY. Diluted EPS was $1.63, up 6%, boosted by a gain from the dissolution of the Glad joint venture business. CEO Shailesh Jejurikar stated: "We delivered a solid acceleration in top-line results in our fiscal third quarter, with broad-based growth across product categories and regions." All five segments posted net sales growth: Beauty +11% ($3.87B), Fabric & Home Care +7% ($7.4B), Baby/Feminine/Family Care +6% ($5.06B), Health Care +7% ($3.07B), and Grooming +7% ($1.61B). The company returned $3.2 billion to shareholders via $2.5 billion in dividends and over $600 million in share repurchases. However, P&G warned about uncertainty from the Iran war's effects on input costs and consumer spending, projecting approximately $400 million in after-tax tariff costs and $150 million in commodity cost headwinds. If Brent crude stays around $100/barrel, P&G projects an annual after-tax headwind of $1 billion. The company will not provide a fiscal 2027 forecast until its July earnings report.

Leadership Transition Impact represents a significant element of P&G's current strategy. Shailesh Jejurikar's appointment as CEO effective January 1, 2026, brings fresh perspectives while maintaining continuity through Jon Moeller's transition to Executive Chairman. Jejurikar described his vision at the CAGNY Conference: leveraging P&G's strengths to "create the CPG company of the future."

Geographic Performance varied across P&G's global markets, with the United States facing particular challenges due to consumer behavior changes and competitive pressures. However, the company's global diversification provides stability, with different regions experiencing varying levels of economic pressure and consumer demand patterns.

Supply Chain and Operations have been optimized to support P&G's productivity initiatives and cost management strategies. The company's integrated supply chain encompasses suppliers, manufacturing partners, and retailers in complex networks ensuring product availability worldwide while maintaining operational efficiency.

Future Outlook remains cautiously optimistic, with P&G maintaining its fiscal year 2026 guidance for all-in sales growth of 1% to 5% and net EPS growth of 1% to 6% versus FY2025 diluted EPS of $6.51. Core EPS growth guidance is in-line to up 4% versus FY2025 core EPS of $6.83, equating to $6.83 to $7.09 per share. However, earnings are expected to trend toward the lower end of the range as cost headwinds persist and investments step up. The company faces approximately $400 million in after-tax tariff costs and $150 million in commodity cost headwinds. P&G will not provide a fiscal 2027 forecast until its July 2026 earnings report, citing uncertainty from the Iran war's impact on input costs and consumer spending.

Investor Confidence remained strong despite mixed results, with P&G shares rising more than 2% in morning trading following the Q2 earnings announcement. This positive market response reflects investor confidence in P&G's ability to navigate current challenges while positioning for future growth through strategic initiatives and operational excellence.

P&G's recent performance demonstrates the company's ability to maintain profitability and shareholder returns while navigating challenging market conditions. The combination of operational efficiency, brand strength, and strategic focus on innovation provides a solid foundation for continued success in the competitive consumer goods industry.

  • Founded: 1837
  • Headquarters: Cincinnati, Ohio, USA
  • Company Type: Publicly Traded
  • Stock: NYSE: PG
  • Revenue: approximately $84 billion (FY2025)
  • Employees: Approximately 107,000

Visit Procter & Gamble Company website

View full company profile for Procter & Gamble Company

Where Is Metamucil Made / Based?

  • Headquarters: Cincinnati, Ohio, United States
  • Manufacturing / Operations: United States, Mexico, India

Metamucil Categories & Tags

Fiber SupplementDigestive HealthPsylliumDietary SupplementOver The CounterProcter Gamble

Metamucil Sustainability & Ethics

Metamucil's sustainability practices are governed by Procter & Gamble's corporate environmental framework. P&G has set goals including 100% of packaging being reusable, recyclable, or compostable, and net zero greenhouse gas emissions across operations and supply chains by 2040. However, these are corporate-level commitments, and Metamucil-specific sustainability metrics are not independently reported.

The brand does not hold independent certifications such as B Corp, organic certification, or fair trade certification. These certifications are not standard in the dietary supplement category. P&G's supplier code of conduct applies to Metamucil suppliers, covering labor practices and environmental compliance.

The primary ingredient, psyllium husk, is sourced from India. P&G's responsible sourcing program includes commitments to sustainable agriculture and supply chain transparency. However, specific details about psyllium farming practices, farmer welfare programs, or environmental impact assessments for Metamucil's supply chain are not publicly available.

Packaging for Metamucil powder containers uses recyclable materials. P&G has reported progress on reducing packaging weight across its portfolio, though brand-specific data for Metamucil is not disclosed.

Awards & Recognition

Metamucil's recognition comes primarily from market position rather than formal industry awards. The brand has been ranked as the number one doctor-recommended fiber brand based on ProVoice survey data from 2023, a recognition that P&G uses prominently in its marketing.

NielsenIQ data has consistently cited Metamucil as the top-selling psyllium fiber supplement in the United States. The brand's 30.2% market share in the fiber supplement category reflects sustained consumer trust and retail performance over its 90-plus year history.

Metamucil does not typically receive product design or innovation awards, as it operates in the functional health category rather than consumer lifestyle segments. Within P&G's portfolio, the brand is recognized as a consistent performer in the Health Care segment, though P&G does not break out individual brand revenue figures publicly.

Metamucil Recalls & Controversies

In February 2024, P&G recalled 257,136 bottles of Metamucil Psyllium Fiber Capsules distributed across 41 states. The recall affected 21,428 cases of the product due to potential microbial contamination concerns. The FDA issued warnings about the affected products, which were removed from retail shelves. P&G cooperated with regulatory authorities and implemented enhanced quality control measures. The recall was classified as Class III, indicating a low probability of adverse health consequences but a situation where exposure could cause temporary or medically reversible adverse effects.

In December 2023, a class-action lawsuit was filed against Procter & Gamble alleging that certain Metamucil products contained dangerous levels of lead. The lawsuit claimed that P&G failed to adequately disclose the presence of lead in its psyllium fiber products. Independent testing by ConsumerLab.com in 2024 found elevated lead levels in some psyllium supplements, raising concerns about heavy metal contamination in the category. The lawsuit remains ongoing as of 2026, with P&G maintaining that its products meet safety standards.

Metamucil products carry FDA-mandated warnings about potential allergic reactions in people sensitive to inhaled or ingested psyllium. Documented cases of occupational asthma and allergic reactions exist among healthcare workers and individuals with repeated psyllium exposure. These warnings are standard for psyllium-based products and are not specific to Metamucil.

The FDA has periodically reviewed Metamucil's marketing claims to ensure compliance with dietary supplement regulations. Health claims related to heart health and cholesterol reduction require FDA authorization. P&G has worked to maintain compliance with evolving regulatory requirements while communicating the scientifically supported benefits of psyllium fiber supplementation.

Brands Owned by Procter & Gamble Company

AlwaysBeauty Personal Care

Always

Owned by Procter & Gamble Company

Procter & Gamble's feminine hygiene brand launched in 1983, holding approximately 27% global market share in menstrual pads and sold in more than 100 countries.

feminine-hygienemenstrual-padspanty-liners
BountyHousehold Consumer Goods

Bounty

Owned by Procter & Gamble Company

American brand of paper towels manufactured by Procter and Gamble since 1965. Known as "the quicker picker-upper" for superior absorbency. P and G's flagship paper towel brand and one of its billion-dollar brands.

paper-towelsabsorbenthousehold
CamayBeauty Personal Care

Camay

Owned by Procter & Gamble Company

American soap brand known for its moisturizing properties, floral scents, and gentle cleansing formulations.

moisturizing-soapfloral-soapbeauty-soap
CascadeHousehold Consumer Goods

Cascade

Owned by Procter & Gamble Company

American dishwashing detergent brand known for its powerful cleaning action and automatic dishwasher formulations.

dishwashing-detergentdishwasher-detergentautomatic-dishwasher
CharminHousehold Consumer Goods

Charmin

Owned by Procter & Gamble Company

American toilet paper brand owned by Procter & Gamble, known for softness and the Charmin Bears advertising campaign.

toilet-paperbathroomhousehold
CheerHousehold Consumer Goods

Cheer

Owned by Procter & Gamble Company

American laundry detergent brand known for its color-safe formula, owned by Procter & Gamble.

laundry-detergentcolor-safefabric-care
View all brands owned by Procter & Gamble Company

Metamucil Ownership: Pros & Cons

Advantages

  • +Access to P&G's global distribution network across 180+ countries and major U.S. retailers
  • +P&G's R&D infrastructure supports clinical research for psyllium fiber health claims
  • +Number one doctor-recommended fiber brand position based on ProVoice survey data
  • +Multiple product formats (powder, capsules, wafers, gummies) covering different consumer preferences
  • +P&G's marketing budget supports television, digital, and healthcare professional outreach

Considerations

  • -Premium pricing compared to private label fiber supplements that hold 16.5% market share
  • -FDA regulatory scrutiny of dietary supplement health claims limits marketing flexibility
  • -Dependency on Indian psyllium husk supply, which is vulnerable to monsoon patterns and crop yields
  • -Competition from Benefiber (GSK) holding 24.8% market share and emerging supplement brands
  • -Ongoing class-action lawsuit regarding lead contamination in psyllium products

Frequently Asked Questions About Metamucil

Sources & Further Reading

  • Procter & Gamble Investor Relations -
  • P&G Environmental Sustainability -
  • The Science Behind Metamucil (P&G) -
  • Metamucil Market Research Report (Emergen Research) -
  • Fiber Supplement Market Trends (Simporter, April 2026) -
  • ConsumerLab Psyllium Fiber Supplement Review -
  • FDA Structured Product Labeling for Metamucil -
  • NielsenIQ Fiber Supplements Market Data -
  • Wikipedia: Procter & Gamble -

Competitors to Metamucil

No direct competitors found in the same category. This could be because Metamuciloperates in a unique market segment or we're still building our competitor database.

Independent Alternatives to Metamucil

Looking for brands with different ownership structures? These similar brands are not owned by Procter & Gamble Company, giving you alternative choices that support different corporate structures.

Pharmacy DirectHealthcare Pharmaceuticals

Pharmacy Direct

Owned by Chempro Chemists

Australian online pharmacy operated by Chempro Chemists from Molendinar, Queensland. Offers prescription medications, health products, and wellness items through digital platforms and mail-order delivery.

online-pharmacymail-orderdigital-health
Privately Owned

Pharmacy Direct is privately owned, unlike Metamucil which is under a publicly traded parent company.

TirosintHealthcare Pharmaceuticals

Tirosint

Owned by IBSA Institut Biochimique S.A.

IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.

levothyroxinehypothyroidismthyroid
Privately Owned

Tirosint is privately owned, unlike Metamucil which is under a publicly traded parent company.

Bausch + LombHealthcare Pharmaceuticals

Bausch + Lomb

Owned by Bausch + Lomb Corporation

Global eye health company and contact lens manufacturer founded in 1853, known for ULTRA, Biotrue One Day, and INFUSE lens lines. Public on NYSE and TSX under BLCO.

contact-lensesvision-carebausch-lomb
Publicly Traded

Bausch + Lomb operates independently without a large parent corporation.

GoodRxHealthcare Pharmaceuticals

GoodRx

Owned by GoodRx Holdings, Inc.

American healthcare technology platform providing prescription drug price comparison, discount coupons, and telehealth services to help consumers find affordable healthcare options.

prescription-savingshealthcare-technologydrug-prices
Publicly Traded

GoodRx operates independently without a large parent corporation.

HerbalifeHealthcare Pharmaceuticals

Herbalife

Owned by Herbalife Ltd.

Global nutrition and weight-management brand owned by Herbalife Ltd. and sold through independent distributors in more than 90 markets.

nutritiondietary-supplementsweight-management
Publicly Traded

Herbalife operates independently without a large parent corporation.

RetavaseHealthcare Pharmaceuticals

Retavase

Owned by EKR Therapeutics, Inc.

Retavase (reteplase) is a prescription thrombolytic medication indicated for acute ST-elevation myocardial infarction. Administered as two 10-unit intravenous bolus injections 30 minutes apart. Currently marketed by Chiesi USA.

pharmaceuticalthrombolyticreteplase
Privately Owned

Retavase is privately owned, unlike Metamucil which is under a publicly traded parent company.

Procter & Gamble Company Stock Information

Jobs at Procter & Gamble Company

Latest News About Metamucil

Related Articles About Metamucil

View more articles
The Complete Guide to Conglomerate Brand Portfolios in 2026
Industry Analysis

The Complete Guide to Conglomerate Brand Portfolios in 2026

LVMH, Unilever, Nestle, P&G, and Berkshire Hathaway own thousands of brands. Discover how these conglomerates structure their portfolios, from luxury to consumer goods. Explore our database.

Who Brands StaffMay 6, 2026
ConglomeratesLvmhUnilever
6 Competing Razor Brands From the Same Parent
Brand Ownership

6 Competing Razor Brands From the Same Parent

Gillette, Venus, and Mach3 are all Procter and Gamble. Schick, Wilkinson Sword, and Hydro Silk are all Edgewell. The razor aisle contains less competition than it appears.

Who Brands StaffApr 3, 2026
Razor BrandsBrand OwnershipProcter Gamble
10 Competing Cleaning Brands Owned by the Same Company
Brand Ownership

10 Competing Cleaning Brands Owned by the Same Company

Lysol vs Dettol. Fairy vs Dawn. Flash vs Mr. Clean. Many cleaning products that appear to compete are owned by the same parent company. Here are 10 examples that will change how you shop.

Who Brands StaffApr 1, 2026
Cleaning BrandsBrand OwnershipSc Johnson
View more articles

People Also Searched

Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.

Abbokinase
Brandpharmaceutical

Abbokinase

Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.

Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Accutane
Branddermatology

Accutane

Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.

Brand in Healthcare & Pharmaceuticals
acne-treatmentprescription
Activase
Brandpharmaceutical

Activase

Activase (alteplase) is a prescription thrombolytic medication manufactured by Genentech, a wholly-owned subsidiary of Roche. Used to treat acute ischemic stroke, heart attack, and pulmonary embolism.

Brand in Healthcare & Pharmaceuticals
thrombolyticstroke-treatment
Browse All Healthcare & Pharmaceuticals

Last reviewed: August 1, 2026 · Reviewed by Who Brands Editorial Team